Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
14 nov. 2022 07h00 HE
|
Lantheus Holdings, Inc.
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
Lantheus to Present at the Jefferies London Healthcare Conference
09 nov. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Reports Third Quarter 2022 Financial Results
03 nov. 2022 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period GAAP net income of $61.2 million for the third quarter 2022, compared to...
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
20 oct. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
17 oct. 2022 09h14 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
13 sept. 2022 08h06 HE
|
Lantheus Holdings, Inc.; GE Healthcare
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)Trial also met its first key secondary endpoint,...
Lantheus to Present at the Wells Fargo Healthcare Conference
01 sept. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative...
Lantheus Reports Second Quarter 2022 Financial Results
04 août 2022 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year periodGAAP net income of $43.1 million for the second quarter 2022, compared to...
Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time
21 juil. 2022 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
15 juin 2022 09h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanchfield has been promoted to...